465 related articles for article (PubMed ID: 28842741)
1. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
[TBL] [Abstract][Full Text] [Related]
3. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
4. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
[TBL] [Abstract][Full Text] [Related]
5. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
6. Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.
Kickingereder P; Isensee F; Tursunova I; Petersen J; Neuberger U; Bonekamp D; Brugnara G; Schell M; Kessler T; Foltyn M; Harting I; Sahm F; Prager M; Nowosielski M; Wick A; Nolden M; Radbruch A; Debus J; Schlemmer HP; Heiland S; Platten M; von Deimling A; van den Bent MJ; Gorlia T; Wick W; Bendszus M; Maier-Hein KH
Lancet Oncol; 2019 May; 20(5):728-740. PubMed ID: 30952559
[TBL] [Abstract][Full Text] [Related]
7. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
[TBL] [Abstract][Full Text] [Related]
8. 18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria.
Bolcaen J; Acou M; Boterberg T; Vanhove C; De Vos F; Van den Broecke C; Van Holen R; Deblaere K; Goethals I
Nucl Med Commun; 2017 Mar; 38(3):242-249. PubMed ID: 27984537
[TBL] [Abstract][Full Text] [Related]
9. Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma.
Gzell CE; Wheeler HR; McCloud P; Kastelan M; Back M
J Neurooncol; 2016 May; 128(1):67-74. PubMed ID: 26879084
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
van Leyen K; Roelcke U; Gruber P; Remonda L; Berberat J
J Neuroimaging; 2019 Sep; 29(5):645-649. PubMed ID: 31112344
[TBL] [Abstract][Full Text] [Related]
11. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
[TBL] [Abstract][Full Text] [Related]
12. Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme.
Kerkhof M; Hagenbeek RE; van der Kallen BF; Lycklama À Nijeholt GJ; Dirven L; Taphoorn MJ; Vos MJ
Eur J Neurol; 2016 Oct; 23(10):1528-33. PubMed ID: 27424939
[TBL] [Abstract][Full Text] [Related]
13. Visual inspection of MR relative cerebral blood volume maps has limited value for distinguishing progression from pseudoprogression in glioblastoma multiforme patients.
Kerkhof M; Tans PL; Hagenbeek RE; Lycklama À Nijeholt GJ; Holla FK; Postma TJ; Straathof CS; Dirven L; Taphoorn MJ; Vos MJ
CNS Oncol; 2017 Oct; 6(4):297-306. PubMed ID: 28984142
[TBL] [Abstract][Full Text] [Related]
14. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
[TBL] [Abstract][Full Text] [Related]
15. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
[TBL] [Abstract][Full Text] [Related]
16. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
17. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
[TBL] [Abstract][Full Text] [Related]
18. Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy.
Larsson C; Groote I; Vardal J; Kleppestø M; Odland A; Brandal P; Due-Tønnessen P; Holme SS; Hope TR; Meling TR; Fosse E; Emblem KE; Bjørnerud A
Magn Reson Imaging; 2020 May; 68():106-112. PubMed ID: 32004711
[TBL] [Abstract][Full Text] [Related]
19. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
[TBL] [Abstract][Full Text] [Related]
20. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
Ellingson BM; Wen PY; Cloughesy TF
Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
